What Does ‘Protection’ against COVID Really Mean?
To answer that question, expanded testing is needed that can determine levels of T immune cells
Esther Landhuis is a freelance science and health journalist based in the San Francisco Bay Area. Follow her on Twitter @elandhuis
To answer that question, expanded testing is needed that can determine levels of T immune cells
An individual’s health risks, treatment access and local case levels come into play for those who are eligible
But shortages mean that new antivirals and other drugs may be hard to come by
Researchers are still puzzling over what this drug does at the molecular level to help COVID patients
Over the past few years, the discipline has evolved in significant ways
New assays could reduce the need for costlier, more invasive brain scans and spinal fluid measures
The antiviral interferon might help early but exacerbate disease in later stages
Biotechs and pharma want to protect patients without triggering immune system havoc
New therapeutics are testing whether protective bacteria can dampen harmful immune responses to food
Clinical trials have begun to test drugs that counter toxic molecular webs linked to lung distress
New research in mice suggests that a pregnancy hormone contributes to brain and behavioral changes caused by childhood adversity
In mice, these white blood cells tamp down inflammation in the lungs
Long-ignored field attracts interest from companies trying to develop next-generation immune therapies
Mouse studies show tiny intercellular pods convey to sperm a legacy of a father’s hard knocks in life
Activating the reward system boosts anti-tumor immunity in mice
Drugs that disrupt production of toxic proteins in the brain could work for various degenerative disorders, including Alzheimer’s and Parkinson’s
Shutting down the top risk gene holds potential for halting the disease process
The computational immunologist Purvesh Khatri embraces messy data as a way to capture the messiness of disease. As a result, he’s making elusive genomic discoveries
A technology that uses magnetism to regulate neural activity shows a small benefit in patients with mild forms of the disease
Biological markers could enable tailored therapies that target individual differences in symptoms
Support science journalism.
Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account